Erlotinib 150 mg
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Squamous Non-Small Cell Lung Cancer
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Trial Timeline
May 1, 2013 → Jan 1, 2016
NCT ID
NCT01836133About Erlotinib 150 mg
Erlotinib 150 mg is a pre-clinical stage product being developed by Roche for Non-Squamous Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01836133. Target conditions include Non-Squamous Non-Small Cell Lung Cancer.
What happened to similar drugs?
3 of 20 similar drugs in Non-Squamous Non-Small Cell Lung Cancer were approved
Approved (3) Terminated (1) Active (16)
❌Camrelizumab;Pemetrexed and Carboplatin; Famitinib; + Camrelizumab;Pemetrexed and Carboplatin;PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01836133 | Pre-clinical | Completed |
Competing Products
20 competing products in Non-Squamous Non-Small Cell Lung Cancer